Oncolytics Biotech says new pelareorep cancer immunotherapy method — of — use patent issues in several countries
Oncolytics disclosed new method-of-use patents issued in several countries covering pelareorep as an immunotherapy for cancer. U.S. issuance is expected soon, extending planned protection for covered uses into the late 2040s, subject to final claims and terms. Manufacturing patent protection runs through 2044, with thr